Robinson et al has published that Epstein-Barr virus infects and reprograms autoreactive B cells to drive the systemic autoimmune response in SLE https://t.co/vjpvILrJOt https://t.co/HepyZrYW5L

Mesothelin as a biomarker and potential therapeutic target in rheumatoid arthritis? Mesothelin is elevated in RA & animal models & promothes osteoclast differentiation & bony destruction. Blocking mesothelin has the potential to reduce bone destruction. https://t.co/WRXG91AqmJ https://t.co/hMgddPXhxG

Day 2 Recap: #ACR25 Highlights Join RheumNow Faculty Drs. David Liew, Antoni Chan, Mrinalini Dey, and Jack Cush as they discuss highlights and key takeaways from the Day 2 Recap. https://t.co/aBxLuDhIMC https://t.co/q75eHf45Gt

CAR-T Therapy: Where is it Heading? Dr. Peter Nash summarizes several abstracts looking at CAR-T therapy from #ACR25. https://t.co/bC8p1LnZMW https://t.co/KKn3jjsBW0

Deep Learning Model Accurately Detects Ankylosing Spondylitis on MRI AI continues to move from research labs into rheumatology clinics, promising to reshape how inflammatory diseases are diagnosed and monitored. AS, in particular, poses a diagnostic challenge—its early imaging https://t.co/TH2YIiPPEq

Sjögren's disease RCTs: Has the Long Drought Ended? At #ACR25, two late breaking abstracts have triggered hope for patients suffering from Sjögren's disease. https://t.co/nNNx5sXzCz https://t.co/r9VBgyYgOC

PRED-SAFE: Shared Decision-Making Tool for Chronic Prednisone Use Drs. Jiha Lee and Shivani Garg discuss abstract 1052 (“Prednisone… A Necessary Evil…” Developing an Evidence-Based Benefits vs. Harms Shared Decision-Making Tool (PRED-SAFE) to Support Decisions Around Chronic https://t.co/ZBH61Uzzc8

Learning just got smarter. Every week, RheumIQ challenges you with a quick quiz on current rheumatology updates. 💡 Educational 🎯 Evidence-based 🧠 Addictive (in a good way) Try it now and level up your clinical knowledge: https://t.co/oa2wxIRGZv https://t.co/wyZYdabM2G

Biologic use in 5008 IBD pts finds higher serious infxn (SIE) rates (vs, RA or PsO). In UC the SIE rate was 5.5/100PY w/ vedolizumab & 7/100PY w/ other biologics. In Crohns the SIE rate was 7.9/100PY w/ vedolizumab vs 6.5/100PY w/ other biologics (adj HR 1.15; 0.95–1.40) (P .16) https://t.co/R7YC220NnO

Genetic Risks and Severe Cutaneous Reactions to Allopurinol A matched cohort study shows that HLA-B*58:01 and HLA-A*34:02 are strongly associated with allopurinol-induced severe cutaneous adverse reactions (SCARs), these alleles were absent in more than one-third of those https://t.co/NLpHVhr9Ww